First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations.

Trial Profile

First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jun 2016 Status changed from active, no longer recruiting to completed, as per results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 08 Jun 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top